Real world experience of treatment and outcome in ALK-rearranged metastatic nonsmall cell lung cancer: A multicenter study from India-Reference-Cited by-同舟云学术

Real world experience of treatment and outcome in ALK-rearranged metastatic nonsmall cell lung cancer: A multicenter study from India

Published:2020-06 Issue:3 Volume:44 Page:100571
ISSN:0147-0272
Container-title:Current Problems in Cancer
language:en
Short-container-title:Current Problems in Cancer

Author:

Patel Amol^ORCID,Batra Ullas,Prasad Kuruswamy Thurai^ORCID,Dabkara Deepak,Ghosh Joydeep^ORCID,Sharma Manasi^ORCID,Singh Navneet^ORCID,Suresh P.,Jain Parveen^ORCID,Malik Prabhat Singh,Choudhary Priyanshu,Ganguly Sandip^ORCID,Khurana Sachin,MS Shivashankara^ORCID,Bothra Sneha^ORCID,Muthu Valliappan,Biswas Bivas^ORCID

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference22 articles.

1. Lung cancer in India: current status and promising strategies;Parikh;South Asian J Cancer,2016

2. Outcomes of patients with unresected stage III and stage IV non-small cell lung cancer: a single institution experience;Tiwana;Lung India Off Organ Indian Chest Soc,2013

3. Clinical and epidemiological study of EGFR mutations and EML4-ALK fusion genes among Indian patients with adenocarcinoma of the lung;Doval;OncoTargets Ther,2015

4. Regional reporting of the incidence of Anaplastic Lymphoma Kinase mutation in 379 non-small-cell lung cancer patients from Kolkata: Using immunohistochemistry as the diagnostic modality in a significant subset;Chatterjee;South Asian J Cancer,2017

5. A study of therapy targeted EGFR/ALK mutations in Indian patients with lung adenocarcinoma: a clinical and epidemiological study;Rana;Med J Armed Forces India,2018

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Uniqueness of lung cancer in Southeast Asia;The Lancet Regional Health - Southeast Asia;2024-08

2. Real-World Treatment and Outcomes in ALK-Rearranged NSCLC: Results From a Large U.S.-Based Database;JTO Clinical and Research Reports;2024-08

3. Real world study of safety and efficacy of lorlatinib as second line and beyond in ALK-rearranged advanced non-small cell lung cancer patients in India – a multicentre chart review study (ROSELAND);ecancermedicalscience;2024-02-13

4. Economic Evaluation of Targeted Therapies for Anaplastic Lymphoma Kinase– and ROS1 Fusion–Positive Non–Small Cell Lung Cancer in India;JCO Global Oncology;2024-02

5. Lung adenocarcinoma with brain metastasis detected dual fusion of LOC399815-ALK and ALK-EML4 in combined treatment of Alectinib and CyberKnife: A case report;Medicine;2024-01-19